<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Cardiovasc Drugs Ther</journal-id><journal-title-group><journal-title>Cardiovascular Drugs and Therapy</journal-title></journal-title-group><issn pub-type="ppub">0920-3206</issn><issn pub-type="epub">1573-7241</issn><publisher><publisher-name>Springer US</publisher-name><publisher-loc>Boston</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">21174145</article-id><article-id pub-id-type="pmc">3070080</article-id><article-id pub-id-type="publisher-id">6273</article-id><article-id pub-id-type="doi">10.1007/s10557-010-6273-5</article-id><article-categories><subj-group subj-group-type="heading"><subject>Article</subject></subj-group></article-categories><title-group><article-title>Achievement of Lipid Targets with the Combination of Rosuvastatin and Fenofibric Acid in Patients with Type 2 Diabetes Mellitus</article-title></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><name><surname>Rosenson</surname><given-names>Robert S.</given-names></name><address><phone>+1-212-6598731</phone><fax>+1-212-6599033</fax><email>robert.rosenson@mssm.edu</email></address><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Carlson</surname><given-names>Dawn M.</given-names></name><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Kelly</surname><given-names>Maureen T.</given-names></name><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Setze</surname><given-names>Carolyn M.</given-names></name><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Hirshberg</surname><given-names>Boaz</given-names></name><xref ref-type="aff" rid="Aff3">3</xref></contrib><contrib contrib-type="author"><name><surname>Stolzenbach</surname><given-names>James C.</given-names></name><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Williams</surname><given-names>Laura A.</given-names></name><xref ref-type="aff" rid="Aff2">2</xref></contrib><aff id="Aff1"><label>1</label>Mount Sinai Heart, Mount Sinai School of Medicine, One Gustave L. Levy Place, New York, NY 10029-6574 USA </aff><aff id="Aff2"><label>2</label>Abbott, Abbott Park, IL USA </aff><aff id="Aff3"><label>3</label>AstraZeneca LP, Wilmington, DE USA </aff></contrib-group><pub-date pub-type="epub"><day>21</day><month>12</month><year>2010</year></pub-date><pub-date pub-type="pmc-release"><day>21</day><month>12</month><year>2010</year></pub-date><pub-date pub-type="ppub"><month>2</month><year>2011</year></pub-date><volume>25</volume><issue>1</issue><fpage>47</fpage><lpage>57</lpage><permissions><copyright-statement>&#x000a9; The Author(s) 2010</copyright-statement></permissions><abstract id="Abs1"><sec><title>Objective</title><p>The objective of this study was to assess the proportion of patients with type 2 diabetes mellitus (T2DM) attaining individual and combined targets of low-density lipoprotein cholesterol (LDL-C), high-density lipoprotein cholesterol (HDL-C), triglycerides (TG), non-HDL-C, and apolipoprotein B (ApoB) after treatment with rosuvastatin (R) + fenofibric acid (FA) compared with corresponding-dose R monotherapy.</p></sec><sec><title>Methods</title><p>This post hoc analysis evaluated data from the T2DM subset of patients with mixed dyslipidemia (LDL-C &#x02265;130&#x000a0;mg/dL, HDL-C &#x0003c;40/50&#x000a0;mg/dL in men/women, and TG &#x02265;150&#x000a0;mg/dL) from 2 randomized studies. Patients included in the analysis (<italic>N</italic>&#x02009;=&#x02009;456) were treated with R (5, 10, or 20&#x000a0;mg), FA 135&#x000a0;mg, or R (5, 10, or 20&#x000a0;mg) + FA 135&#x000a0;mg for 12&#x000a0;weeks. Attainment of LDL-C &#x0003c;100&#x000a0;mg/dL, HDL-C &#x0003e;40/50&#x000a0;mg/dL in men/women, TG &#x0003c;150&#x000a0;mg/dL, non-HDL-C &#x0003c;130&#x000a0;mg/dL, ApoB &#x0003c;90&#x000a0;mg/dL, and the combined targets of these parameters was assessed.</p></sec><sec><title>Results</title><p>Treatment with R + FA resulted in a significantly higher proportion of patients achieving optimal levels of HDL-C (46.8% vs. 20.8%, <italic>P</italic>&#x02009;=&#x02009;0.009 for R 10&#x000a0;mg + FA), TG (60.0% vs. 34.0%, <italic>P</italic>&#x02009;=&#x02009;0.02 for R 10&#x000a0;mg + FA; 54.0% vs. 26.4%, <italic>P</italic>&#x02009;=&#x02009;0.005 for R 20&#x000a0;mg + FA), non-HDL-C (55.1% vs. 36.4%, <italic>P</italic>&#x02009;=&#x02009;0.04 for R 5&#x000a0;mg + FA), ApoB (58.0% vs. 36.4%, <italic>P</italic>&#x02009;=&#x02009;0.02 for R 5&#x000a0;mg + FA); and the combined targets of LDL-C, HDL-C, and TG (28.3% vs. 8.3%, <italic>P</italic>&#x02009;=&#x02009;0.02 for R 10&#x000a0;mg + FA) and all 5 parameters (26.1% vs. 8.3%, <italic>P</italic>&#x02009;=&#x02009;0.03 for R 10&#x000a0;mg + FA) than corresponding-dose R monotherapies.</p></sec><sec><title>Conclusions</title><p>A significantly greater proportion of T2DM patients achieved individual and combined lipid targets when treated with the combination of R + FA than corresponding-dose R monotherapies.</p></sec></abstract><kwd-group><title>Key words</title><kwd>Fibrates</kwd><kwd>Statins</kwd><kwd>Dyslipidemia</kwd></kwd-group><custom-meta-group><custom-meta><meta-name>issue-copyright-statement</meta-name><meta-value>&#x000a9; Springer Science+Business Media, LLC 2011</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="Sec1"><title>Introduction</title><p>Patients with type 2 diabetes mellitus (T2DM) are at increased risk for atherosclerotic cardiovascular disease (CVD) and associated morbidity and mortality [<xref ref-type="bibr" rid="CR1">1</xref>]. This is likely attributable to a common clustering of CVD risk factors underlying insulin resistance including dyslipidemia, hypertension, hyperglycemia, and a prothrombotic/proinflammatory state [<xref ref-type="bibr" rid="CR2">2</xref>]. The characteristic dyslipidemic profile seen in patients with T2DM includes elevated triglycerides (TG), low levels of high-density lipoprotein cholesterol (HDL-C), and modestly elevated levels of low-density lipoprotein cholesterol (LDL-C), with an increased number of small dense LDL particles [<xref ref-type="bibr" rid="CR3">3</xref>&#x02013;<xref ref-type="bibr" rid="CR5">5</xref>].</p><p>The National Cholesterol Education Program (NCEP) Adult Treatment Panel III (ATP III) recommends that patients with DM achieve as a primary target of therapy an LDL-C &#x0003c;100&#x000a0;mg/dL and as a secondary target of therapy a non-HDL-C &#x0003c;130&#x000a0;mg/dL if hypertriglyceridemia (TG &#x02265;200&#x000a0;mg/dL) is present [<xref ref-type="bibr" rid="CR6">6</xref>]. Additionally, the American Diabetes Association has recommended optimal values for TG of &#x0003c;150&#x000a0;mg/dL and for HDL-C of &#x0003e;40&#x000a0;mg/dL in men and &#x0003e;50&#x000a0;mg/dL in women [<xref ref-type="bibr" rid="CR7">7</xref>]. A consensus statement on lipoprotein management from the ADA and the American College of Cardiology specified non-HDL-C and apolipoprotein B (ApoB) treatment goals of &#x02009;&#x0003c;130&#x000a0;mg/dL and &#x0003c;90&#x000a0;mg/dL, respectively, in patients with DM [<xref ref-type="bibr" rid="CR3">3</xref>]. In the presence of DM and at least one additional major CVD risk factor, more aggressive goals apply [<xref ref-type="bibr" rid="CR3">3</xref>, <xref ref-type="bibr" rid="CR8">8</xref>].</p><p>Although therapeutic lifestyle changes may constitute initial therapy for patients with T2DM and lipoprotein abnormalities, most patients also will likely require pharmacotherapy to achieve lipid targets [<xref ref-type="bibr" rid="CR2">2</xref>]. Statin monotherapy, appropriately, is often the initial therapy of choice; however, maximally tolerated doses of statins often fail to achieve desired lipid targets beyond LDL-C, and treatment combining a statin with another lipid-modifying agent may be required [<xref ref-type="bibr" rid="CR7">7</xref>, <xref ref-type="bibr" rid="CR9">9</xref>]. One such therapeutic approach is to combine a statin with fenofibric acid (FA). Fenofibric acid choline salt formulated as enteric-coated mini-tablets in a delayed-release capsule is approved for combined use with a statin to reduce TG and increase HDL-C in patients with mixed dyslipidemia and coronary heart disease (CHD) or a CHD risk equivalent, who are on optimal statin therapy to achieve their LDL-C goal.</p><p>Two controlled clinical studies of patients with mixed dyslipidemia evaluated the efficacy and safety of combination therapy with rosuvastatin (R) 5, 10 or 20&#x000a0;mg + FA for 12&#x000a0;weeks compared with individual monotherapies [<xref ref-type="bibr" rid="CR10">10</xref>, <xref ref-type="bibr" rid="CR11">11</xref>]. In both studies, treatment with R (at each dose) + FA was found to be efficacious and generally well tolerated. We present here the results of a post hoc analysis on achievement of individual and combined lipid and lipoprotein targets with R 5, 10, or 20&#x000a0;mg + FA combination therapy compared with corresponding-dose R monotherapies in the subset of patients with T2DM from the aforementioned two studies.</p></sec><sec id="Sec2" sec-type="methods"><title>Patients and methods</title><sec id="Sec3"><title>Patients</title><p>This analysis includes patients with T2DM from two phase 3, randomized, controlled studies that compared the efficacy and safety of combination therapy with R 5&#x000a0;mg + FA 135&#x000a0;mg (Study 1; NCT00463606) and R 10 or 20&#x000a0;mg + FA 135&#x000a0;mg (Study 2; NCT00300482) to FA and corresponding-dose R monotherapies in patients with mixed dyslipidemia [<xref ref-type="bibr" rid="CR10">10</xref>, <xref ref-type="bibr" rid="CR11">11</xref>]. The studies randomized patients at 349 sites in North America. The protocol for each study was approved by appropriate ethics committees and review boards, and all patients provided written informed consent.</p><p>Men and nonpregnant women &#x02265;18&#x000a0;years of age with fasting lipid results of TG &#x02265;150&#x000a0;mg/dL, HDL-C &#x0003c;40&#x000a0;mg/dL for men or &#x0003c;50&#x000a0;mg/dL for women, and LDL-C &#x02265;130&#x000a0;mg/dL were included in each study. Patients with hemoglobin A1c &#x02264;10.5% in Study 1 and &#x02264;8.5% in Study 2 were included. Additional eligibility criteria have been published [<xref ref-type="bibr" rid="CR12">12</xref>].</p></sec><sec id="Sec4"><title>Study design</title><p>In Study 1, eligible patients were randomized in a double-blind 1:1:1 ratio to R 5&#x000a0;mg, FA 135&#x000a0;mg, or R 5&#x000a0;mg + FA 135&#x000a0;mg [<xref ref-type="bibr" rid="CR10">10</xref>]. In Study 2, eligible patients were randomized in a double-blind 2:2:2:2:2:1 ratio to R 10 or 20&#x000a0;mg, FA 135&#x000a0;mg, R 10 or 20&#x000a0;mg + FA 135&#x000a0;mg, or R 40&#x000a0;mg [<xref ref-type="bibr" rid="CR11">11</xref>]. The R 40&#x000a0;mg group was included in Study 2 as a reference for efficacy and safety assessments and except for comparisons of baseline characteristics was not included in any statistical comparisons. Study design was identical in both studies except for the R dose(s) used. All drugs were self-administered once daily at approximately the same time of day with or without food. In both studies, randomization was stratified by diabetic status and screening TG level (&#x02264;250&#x000a0;mg/dL or &#x0003e;250&#x000a0;mg/dL). Diagnosis of T2DM was based on the investigators&#x02019; assessment of medical history and/or fasting glucose measurement at screening. Patients and site and sponsor personnel were blinded to lipid parameter results obtained after the baseline visit.</p><p>Both studies consisted of a 6-week diet/lipid-altering medication washout screening period, a 12-week treatment period, and a 30-day safety evaluation period. Patients stopped any lipid-altering medications and were expected to follow the American Heart Association diet [<xref ref-type="bibr" rid="CR13">13</xref>]. A week before randomization, fasting (&#x02265;12&#x000a0;h) blood lipid profiles were obtained to determine eligibility. Additional fasting blood samples for efficacy analyses were obtained at the randomization visit, two interim visits (weeks 4 and 8 of the treatment period), and the final visit (week 12 or earlier for premature discontinuation). Samples were analyzed at Covance Central Laboratory Services (Indianapolis, IN, USA). Additional study details have been published [<xref ref-type="bibr" rid="CR10">10</xref>&#x02013;<xref ref-type="bibr" rid="CR12">12</xref>].</p></sec><sec id="Sec5"><title>Statistical analysis</title><p>Data collected for patients with a diagnosis of T2DM at randomization from the two studies were included in this analysis; only data from the FA monotherapy group were integrated across the two studies. Of a total of 2197&#x000a0;patients randomized in the two studies, 498 (23%) had T2DM and were treated.</p><p>Last observation carried forward method was used to impute values for patients with missing postbaseline values. The number and percentage of patients attaining individual lipid targets of LDL-C &#x0003c;100&#x000a0;mg/dL, HDL-C &#x0003e;40&#x000a0;mg/dL (men) or &#x0003e;50&#x000a0;mg/dL (women), TG &#x0003c;150&#x000a0;mg/dL, non-HDL-C &#x0003c;130&#x000a0;mg/dL, and ApoB &#x0003c;90&#x000a0;mg/dL, and the combined lipid target of two (LDL-C and non-HDL-C), three (LDL-C, HDL-C, and TG), and five (LDL-C, HDL-C, TG, non-HDL-C, and ApoB) parameters at the final visit were compared between each combination-therapy group and the corresponding-dose R monotherapy group using Fisher&#x02019;s exact test. Patients were not required to have a corresponding baseline value for the summaries of lipid targets. As a sensitivity analysis, a logistic regression analysis of each individual lipid target, in which treatment group and the corresponding baseline value were included as independent variables in the model, was performed.</p><p>Statistical comparisons of percent changes in lipid and nonlipid parameters were performed as previously described [<xref ref-type="bibr" rid="CR11">11</xref>]. For HDL-C, TG, ApoB, and high-sensitivity C-reactive protein (hsCRP), R + FA was compared with corresponding-dose R monotherapy (primary comparison); for LDL-C, the primary comparison was with FA monotherapy. For non-HDL-C, the primary comparisons were between R + FA and FA, followed by a comparison with the corresponding-dose R monotherapy. Data were analyzed using SAS version 8.2 (SAS Institute, Inc., Cary, NC, USA).</p></sec></sec><sec id="Sec6"><title>Results</title><p>Of 499 patients with T2DM randomized in the two studies, 498 were treated, and 438 completed their respective study (Fig.&#x000a0;<xref rid="Fig1" ref-type="fig">1</xref>). A total of 456 patients, excluding the R 40&#x000a0;mg arm, had postbaseline efficacy data and were, therefore, included in the analysis evaluating attainment of lipid targets. Baseline demographic and clinical characteristics were similar across all groups (Table&#x000a0;<xref rid="Tab1" ref-type="table">1</xref>). Overall (including patients in the R 40&#x000a0;mg group), approximately 70% of patients were &#x0003c;65&#x000a0;years of age; at least 85% of patients in each group weighed &#x02265;70&#x000a0;kg. The incidence of comorbidities was consistent with the increased risk for CVD in this patient population. The most frequently used (&#x0003e;10% overall) DM medications at baseline included metformin (51.4%), glipizide (12.9%), pioglitazone (11.2%), and rosiglitazone (11.4%); no statistically significant differences were observed among the treatment groups in the frequency of the most commonly used diabetic medications at baseline. During the treatment period, metformin was initiated by one or more patients in each treatment group except R 10&#x000a0;mg + FA (3.4% overall). Glipizide, pioglitazone, and rosiglitazone were initiated by 0.8%, 1.6%, and 0.6% of patients, respectively during the treatment period. There were no statistically significant differences between the combination therapy arms and the corresponding rosuvastatin monotherapy arms in the frequency of initiating any of these four diabetic medications during the 12-week treatment period.
<fig id="Fig1"><label>Fig.&#x000a0;1</label><caption><p>Patient flowchart. <sup>a</sup>The R 40&#x000a0;mg group was not included in predefined statistical comparisons. <sup>b</sup>Patients may have been counted for more than one reason for discontinuation. <sup>c</sup>Other reasons for discontinuation included: FA: protocol violation and physician decision; R 5&#x000a0;mg: protocol violation; R 5&#x000a0;mg + FA: error by study coordinator, patient randomized in error, and physician decision; R 10&#x000a0;mg: personal reason, investigator decision, and physician decision; R 10&#x000a0;mg + FA: concomitant illness; and R 20&#x000a0;mg + FA: investigator decision, physician decision, and patient unable to comply with protocol. FA, fenofibric acid 135&#x000a0;mg; R, rosuvastatin (5, 10, or 20&#x000a0;mg)</p></caption><graphic xlink:href="10557_2010_6273_Fig1_HTML" id="MO1"/></fig><table-wrap id="Tab1"><label>Table&#x000a0;1</label><caption><p>Demographics and baseline characteristics</p></caption><table frame="hsides" rules="groups"><thead><tr><th>Characteristic</th><th>FA 135&#x000a0;mg (<italic>n</italic>&#x02009;=&#x02009;123)</th><th>R 5&#x000a0;mg (<italic>n</italic>&#x02009;=&#x02009;68)</th><th>R 5&#x000a0;mg + FA (<italic>n</italic>&#x02009;=&#x02009;73)</th><th>R 10&#x000a0;mg (<italic>n</italic>&#x02009;=&#x02009;52)</th><th>R 10&#x000a0;mg + FA (<italic>n</italic>&#x02009;=&#x02009;52)</th><th>R 20&#x000a0;mg (<italic>n</italic>&#x02009;=&#x02009;53)</th><th>R 20&#x000a0;mg + FA (<italic>n</italic>&#x02009;=&#x02009;52)</th></tr></thead><tbody><tr><td colspan="8">Sex, n (%)</td></tr><tr><td>Male</td><td>54 (43.9)</td><td>21 (30.9)</td><td>24 (32.9)</td><td>23 (44.2)</td><td>21 (40.4)</td><td>30 (56.6)</td><td>23 (44.2)</td></tr><tr><td colspan="8">Race, n (%)</td></tr><tr><td>White</td><td>113 (91.9)</td><td>56 (82.4)</td><td>67 (91.8)</td><td>47 (90.4)</td><td>46 (88.5)</td><td>43 (81.1)</td><td>45 (86.5)</td></tr><tr><td>Black</td><td>9 (7.3)</td><td>12 (17.6)</td><td>2 (2.7)</td><td>4 (7.7)</td><td>6 (11.5)</td><td>8 (15.1)</td><td>5 (9.6)</td></tr><tr><td>Other</td><td>1 (0.8)</td><td>0</td><td>4 (5.5)</td><td>1 (1.9)</td><td>0</td><td>2 (3.8)</td><td>2 (3.8)</td></tr><tr><td colspan="8">Age (years)</td></tr><tr><td>Mean &#x000b1; SD</td><td>57.6&#x02009;&#x000b1;&#x02009;10.36</td><td>58.1&#x02009;&#x000b1;&#x02009;9.57</td><td>61.0&#x02009;&#x000b1;&#x02009;9.54</td><td>58.6&#x02009;&#x000b1;&#x02009;9.68</td><td>59.9&#x02009;&#x000b1;&#x02009;9.76</td><td>58.2&#x02009;&#x000b1;&#x02009;10.95</td><td>58.8&#x02009;&#x000b1;&#x02009;10.12</td></tr><tr><td>Range</td><td>29&#x02013;82</td><td>39&#x02013;79</td><td>29&#x02013;79</td><td>36&#x02013;80</td><td>34&#x02013;83</td><td>31&#x02013;82</td><td>35&#x02013;82</td></tr><tr><td colspan="8">Body weight (kg), n (%)</td></tr><tr><td>&#x0003c;70</td><td>15 (12.2)</td><td>8 (11.8)</td><td>8 (11.0)</td><td>4 (7.7)</td><td>7 (13.5)</td><td>2 (3.8)</td><td>1 (1.9)</td></tr><tr><td>Waist circumference, (cm)</td><td><italic>n</italic>&#x02009;=&#x02009;122</td><td><italic>n</italic>&#x02009;=&#x02009;67</td><td><italic>n</italic>&#x02009;=&#x02009;73</td><td><italic>n</italic>&#x02009;=&#x02009;50</td><td><italic>n</italic>&#x02009;=&#x02009;52</td><td><italic>n</italic>&#x02009;=&#x02009;53</td><td><italic>n</italic>&#x02009;=&#x02009;51</td></tr><tr><td>Mean &#x000b1; SD</td><td>107.5&#x02009;&#x000b1;&#x02009;16.50</td><td>108.1&#x02009;&#x000b1;&#x02009;15.94</td><td>111.6&#x02009;&#x000b1;&#x02009;18.31</td><td>112.7&#x02009;&#x000b1;&#x02009;13.48</td><td>110.4&#x02009;&#x000b1;&#x02009;20.31</td><td>108.2&#x02009;&#x000b1;&#x02009;13.24</td><td>111.6&#x02009;&#x000b1;&#x02009;16.06</td></tr><tr><td colspan="8">Comorbidities, n (%)<sup>a</sup></td></tr><tr><td>CAD</td><td>16 (13.0)</td><td>6 (8.8)</td><td>6 (8.2)</td><td>6 (11.5)</td><td>6 (11.5)</td><td>10 (18.9)</td><td>4 (7.7)</td></tr><tr><td>Hypertension</td><td>93 (75.6)</td><td>47 (69.1)</td><td>54 (74.0)</td><td>40 (76.9)</td><td>42 (80.8)</td><td>40 (75.5)</td><td>40 (76.9)</td></tr><tr><td>Metabolic syndrome<sup>b</sup></td><td>102 (82.9)</td><td>56 (82.4)</td><td>65 (89.0)</td><td>47 (90.4)</td><td>49 (94.2)</td><td>47 (88.7)</td><td>48 (92.3)</td></tr><tr><td>Obesity</td><td>39 (31.7)</td><td>30 (44.1)</td><td>27 (37.0)</td><td>21 (40.4)</td><td>18 (34.6)</td><td>22 (41.5)</td><td>18 (34.6)</td></tr><tr><td colspan="8">DM medication, n (%)<sup>c</sup></td></tr><tr><td>Metformin</td><td>64 (52.0)</td><td>38 (55.9)</td><td>38 (52.1)</td><td>22 (42.3)</td><td>28 (53.8)</td><td>26 (49.1)</td><td>26 (50.0)</td></tr><tr><td>Glipizide</td><td>17 (13.8)</td><td>6 (8.8)</td><td>8 (11.0)</td><td>6 (11.5)</td><td>6 (11.5)</td><td>6 (11.3)</td><td>13 (25.0)</td></tr><tr><td>Pioglitazone</td><td>15 (12.2)</td><td>7 (10.3)</td><td>7 (9.6)</td><td>6 (11.5)</td><td>7 (13.5)</td><td>5 (9.4)</td><td>6 (11.5)</td></tr><tr><td>Rosiglitazone</td><td>14 (11.4)</td><td>3 (4.4)</td><td>5 (6.8)</td><td>8 (15.4)</td><td>5 (9.6)</td><td>9 (17.0)</td><td>7 (13.5)</td></tr><tr><td>Mean lipid values, mg/dL</td><td/><td/><td/><td/><td/><td/><td/></tr><tr><td rowspan="2">LDL-C</td><td><italic>n</italic>&#x02009;=&#x02009;123</td><td><italic>n</italic>&#x02009;=&#x02009;68</td><td><italic>n</italic>&#x02009;=&#x02009;73</td><td><italic>n</italic>&#x02009;=&#x02009;52</td><td><italic>n</italic>&#x02009;=&#x02009;52</td><td><italic>n</italic>&#x02009;=&#x02009;53</td><td><italic>n</italic>&#x02009;=&#x02009;52</td></tr><tr><td>153.2</td><td>147.7</td><td>146.2</td><td>146.4</td><td>148.0</td><td>152.1</td><td>154.3</td></tr><tr><td rowspan="2">HDL-C<sup>d</sup></td><td><italic>n</italic>&#x02009;=&#x02009;120</td><td><italic>n</italic>&#x02009;=&#x02009;68</td><td><italic>n</italic>&#x02009;=&#x02009;73</td><td><italic>n</italic>&#x02009;=&#x02009;50</td><td><italic>n</italic>&#x02009;=&#x02009;50</td><td><italic>n</italic>&#x02009;=&#x02009;51</td><td><italic>n</italic>&#x02009;=&#x02009;51</td></tr><tr><td>39.4</td><td>41.4</td><td>40.3</td><td>36.9</td><td>38.4</td><td>37.6</td><td>38.5</td></tr><tr><td rowspan="2">TG</td><td><italic>n</italic>&#x02009;=&#x02009;123</td><td><italic>n</italic>&#x02009;=&#x02009;68</td><td><italic>n</italic>&#x02009;=&#x02009;73</td><td><italic>n</italic>&#x02009;=&#x02009;52</td><td><italic>n</italic>&#x02009;=&#x02009;52</td><td><italic>n</italic>&#x02009;=&#x02009;53</td><td><italic>n</italic>&#x02009;=&#x02009;52</td></tr><tr><td>271.9</td><td>308.8</td><td>306.2</td><td>316.7</td><td>307.6</td><td>300.7</td><td>286.0</td></tr><tr><td rowspan="2">ApoB<sup>e</sup></td><td><italic>n</italic>&#x02009;=&#x02009;121</td><td><italic>n</italic>&#x02009;=&#x02009;68</td><td><italic>n</italic>&#x02009;=&#x02009;73</td><td><italic>n</italic>&#x02009;=&#x02009;51</td><td><italic>n</italic>&#x02009;=&#x02009;52</td><td><italic>n</italic>&#x02009;=&#x02009;52</td><td><italic>n</italic>&#x02009;=&#x02009;52</td></tr><tr><td>138.6</td><td>133.6</td><td>130.8</td><td>143.9</td><td>142.7</td><td>146.2</td><td>143.8</td></tr></tbody></table><table-wrap-foot><p><italic>FA</italic> fenofibric acid; <italic>R</italic> rosuvastatin; <italic>CAD</italic> coronary artery disease; <italic>LDL-C</italic> low-density lipoprotein cholesterol; <italic>HDL-C</italic> high-density lipoprotein cholesterol; <italic>TG</italic> triglycerides; <italic>ApoB</italic> apolipoprotein B; <italic>DM</italic> diabetes mellitus.</p><p><sup>a</sup>Comorbidities were obtained from medical history.</p><p><sup>b</sup>Metabolic syndrome criteria are as described in the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report [<xref ref-type="bibr" rid="CR6">6</xref>].</p><p><sup>c</sup>Most frequently used DM medications (incidence &#x0003e;10% overall) at baseline.</p><p><sup>d</sup>Statistically significant difference in baseline HDL-C values among treatment groups (<italic>P</italic>&#x02009;=&#x02009;0.04).</p><p><sup>e</sup>Statistically significant difference in baseline ApoB values among treatment groups (<italic>P</italic>&#x02009;=&#x02009;0.003).</p></table-wrap-foot></table-wrap></p><p>Achievement of individual and combined lipid targets with R + FA combination therapy and R and FA monotherapies is shown in Figs.&#x000a0;<xref rid="Fig2" ref-type="fig">2</xref> and <xref rid="Fig3" ref-type="fig">3</xref>. No statistically significant differences were observed in the proportion of patients achieving the LDL-C goal of &#x0003c;100&#x000a0;mg/dL between any combination-therapy group and the corresponding-dose R monotherapy group. Treatment with R 10&#x000a0;mg + FA resulted in a significantly higher proportion of patients achieving their individual HDL-C target (46.8% vs. 20.8%, <italic>P</italic>&#x02009;=&#x02009;0.009) than R 10&#x000a0;mg. The individual TG target was achieved by a significantly higher proportion of patients treated with R 10&#x000a0;mg + FA (60.0% vs. 34.0%, <italic>P</italic>&#x02009;=&#x02009;0.02) and R 20&#x000a0;mg + FA (54.0% vs. 26.4%, <italic>P</italic>&#x02009;=&#x02009;0.005) versus the corresponding-dose R monotherapies. The differences for the proportion of patients who achieved the individual non-HDL-C target (55.1% vs. 36.4%, <italic>P</italic>&#x02009;=&#x02009;0.04) and the individual ApoB target (58.0% vs. 36.4%, <italic>P</italic>&#x02009;=&#x02009;0.02) were significant between R 5&#x000a0;mg + FA and R 5&#x000a0;mg. The combined target of LDL-C and non-HDL-C was achieved by 49.3% of patients treated with R 5&#x000a0;mg + FA versus 34.8% of patients treated with R 5-mg monotherapy (<italic>P</italic>&#x02009;=&#x02009;0.12) and by 70.2% of patients treated with R 20&#x000a0;mg + FA versus 66.7% of patients treated with R 20-mg monotherapy (<italic>P</italic>&#x02009;=&#x02009;0.83). Treatment with R 10&#x000a0;mg + FA resulted in a significantly higher proportion of patients achieving the combined target of LDL-C, HDL-C, and TG (28.3% vs. 8.3%, <italic>P</italic>&#x02009;=&#x02009;0.02) versus R 10&#x000a0;mg. Similarly, combination therapy with R 10&#x000a0;mg + FA resulted in a significantly higher proportion of patients achieving the combined target of all five parameters (26.1% vs. 8.3%, <italic>P</italic>&#x02009;=&#x02009;0.03) versus R 10&#x000a0;mg (Fig.&#x000a0;<xref rid="Fig3" ref-type="fig">3</xref>). The results of sensitivity analyses adjusting for the baseline value were similar. In addition to the statistically significant differences noted above for the individual targets, sensitivity analyses demonstrated statistically significant differences favoring R 5&#x000a0;mg + FA versus R 5&#x000a0;mg for the HDL-C target (odds ratio: 2.2; 95% CI: 1.0, 4.6; <italic>P</italic>&#x02009;=&#x02009;0.04), and favoring R 10&#x000a0;mg versus R 10&#x000a0;mg + FA for the LDL-C target (odds ratio: 0.4; 95% CI: 0.1, 1.0; <italic>P</italic>&#x02009;=&#x02009;0.05).
<fig id="Fig2"><label>Fig.&#x000a0;2</label><caption><p><bold>a&#x02013;e</bold>. Proportion of T2DM patients achieving individual target of (<bold>a</bold>) LDL-C &#x0003c;100&#x000a0;mg/dL; (<bold>b</bold>) HDL-C &#x0003e;40/50&#x000a0;mg/dL in men/women; (<bold>c</bold>) TG &#x0003c;150&#x000a0;mg/dL; (<bold>d</bold>) non-HDL-C &#x0003c;130&#x000a0;mg/dL; and (<bold>e</bold>) ApoB &#x0003c;90&#x000a0;mg/dL at final visit. <italic>P</italic>-values were obtained using Fisher&#x02019;s exact test to test for a difference between each rosuvastatin (R) + fenofibric acid (FA) combination-therapy group and the corresponding-dose R monotherapy group. ApoB, apolipoprotein B; FA, fenofibric acid 135&#x000a0;mg; HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol; R, rosuvastatin (5, 10, or 20&#x000a0;mg); T2DM, type 2 diabetes mellitus; TG, triglycerides</p></caption><graphic xlink:href="10557_2010_6273_Fig2_HTML" id="MO2"/></fig><fig id="Fig3"><label>Fig.&#x000a0;3</label><caption><p><bold>a&#x02013;c</bold>. Proportion of T2DM patients achieving combined targets of (<bold>a</bold>) LDL-C and non-HDL-C; (<bold>b</bold>) LDL-C, HDL-C, and TG; and (<bold>c</bold>) LDL-C, HDL-C, TG, non-HDL-C, and ApoB. Targets were defined as LDL-C &#x0003c;100&#x000a0;mg/dL, HDL-C &#x0003e;40/50&#x000a0;mg/dL in men/women, TG &#x0003c;150&#x000a0;mg/dL, non-HDL-C &#x0003c;130&#x000a0;mg/dL, and ApoB &#x0003c;90&#x000a0;mg/dL at final visit. ApoB, apolipoprotein B; FA, fenofibric acid 135&#x000a0;mg; HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol; R, rosuvastatin (5, 10, or 20&#x000a0;mg); T2DM, type 2 diabetes mellitus; TG, triglycerides</p></caption><graphic xlink:href="10557_2010_6273_Fig3_HTML" id="MO3"/></fig></p><p>R + FA combination therapy resulted in statistically significant greater mean percent increases in HDL-C (25.5% vs. 17.0%, <italic>P</italic>&#x02009;=&#x02009;0.02 for R 5&#x000a0;mg + FA and 19.6% vs. 5.7%, <italic>P</italic>&#x02009;=&#x02009;0.002 for R 10&#x000a0;mg + FA) compared with R 5- or 10-mg monotherapies, respectively (Table&#x000a0;<xref rid="Tab2" ref-type="table">2</xref>). All three doses of R + FA resulted in statistically significant greater mean percent decreases in TG (39.9% vs. 23.6%, <italic>P</italic>&#x02009;&#x0003c;&#x02009;0.001 for R 5&#x000a0;mg + FA; 44.8% vs. 28.6%, <italic>P</italic>&#x02009;=&#x02009;0.002 for R 10&#x000a0;mg + FA; and 42.6% vs. 26.9%, <italic>P</italic>&#x02009;=&#x02009;0.002 for R 20&#x000a0;mg + FA) than corresponding dose of R. Compared with R 5&#x000a0;mg, reductions in non-HDL-C (41.1% vs. 33.5%, <italic>P</italic>&#x02009;=&#x02009;0.004) and ApoB (34.9% vs. 28.1%, <italic>P</italic>&#x02009;=&#x02009;0.008) were significant with R 5&#x000a0;mg + FA, but not with the higher doses of R + FA versus corresponding-dose R monotherapies.
<table-wrap id="Tab2"><label>Table&#x000a0;2</label><caption><p>Percent change from baseline to final visit in efficacy parameters</p></caption><table frame="hsides" rules="groups"><thead><tr><th>Variable</th><th>FA 135&#x000a0;mg</th><th>R 5&#x000a0;mg</th><th>R 5&#x000a0;mg + FA</th><th>R 10&#x000a0;mg</th><th>R 10&#x000a0;mg + FA</th><th>R 20&#x000a0;mg</th><th>R 20&#x000a0;mg + FA</th></tr></thead><tbody><tr><td>HDL-C</td><td><italic>n</italic>&#x02009;=&#x02009;114</td><td><italic>n</italic>&#x02009;=&#x02009;66</td><td><italic>n</italic>&#x02009;=&#x02009;69</td><td><italic>n</italic>&#x02009;=&#x02009;46</td><td><italic>n</italic>&#x02009;=&#x02009;45</td><td><italic>n</italic>&#x02009;=&#x02009;49</td><td><italic>n</italic>&#x02009;=&#x02009;46</td></tr><tr><td>&#x000a0;&#x000a0;Baseline mean, mg/dL</td><td>39.3</td><td>41.1</td><td>40.3</td><td>36.8</td><td>38.4</td><td>37.7</td><td>38.6</td></tr><tr><td>&#x000a0;&#x000a0;Final mean, mg/dL</td><td>46.5</td><td>46.3</td><td>49.2</td><td>39.3</td><td>46.1</td><td>41.1</td><td>44.5</td></tr><tr><td>&#x000a0;&#x000a0;Mean change, % (SE)</td><td>19.0 (2.03)</td><td>17.0 (2.68)</td><td>25.5 (2.61)</td><td>5.7 (3.20)</td><td>19.6 (3.24)</td><td>11.0 (3.10)</td><td>16.4 (3.19)</td></tr><tr><td>&#x000a0;&#x000a0;<italic>P</italic>-value<sup>a</sup></td><td/><td/><td>0.02<sup>c</sup></td><td/><td>0.002<sup>c</sup></td><td/><td>0.22<sup>c</sup></td></tr><tr><td>TG</td><td><italic>n</italic>&#x02009;=&#x02009;118</td><td><italic>n</italic>&#x02009;=&#x02009;66</td><td><italic>n</italic>&#x02009;=&#x02009;69</td><td><italic>n</italic>&#x02009;=&#x02009;50</td><td><italic>n</italic>&#x02009;=&#x02009;50</td><td><italic>n</italic>&#x02009;=&#x02009;53</td><td><italic>n</italic>&#x02009;=&#x02009;50</td></tr><tr><td>&#x000a0;&#x000a0;Baseline mean, mg/dL</td><td>272.8</td><td>311.2</td><td>306.7</td><td>320.8</td><td>304.0</td><td>300.4</td><td>285.4</td></tr><tr><td>&#x000a0;&#x000a0;Final mean, mg/dL</td><td>164.6</td><td>207.0</td><td>157.5</td><td>218.5</td><td>169.1</td><td>195.2</td><td>152.0</td></tr><tr><td>&#x000a0;&#x000a0;Mean change, % (SE)</td><td>&#x02212;34.5 (2.41)</td><td>&#x02212;23.6 (3.20)</td><td>&#x02212;39.9 (3.13)</td><td>&#x02212;28.6 (3.68)</td><td>&#x02212;44.8 (3.68)</td><td>&#x02212;26.9 (3.57)</td><td>&#x02212;42.6 (3.68)</td></tr><tr><td>&#x000a0;&#x000a0;<italic>P</italic>-value<sup>a</sup></td><td/><td/><td>&#x0003c;0.001<sup>c</sup></td><td/><td>0.002<sup>c</sup></td><td/><td>0.002<sup>c</sup></td></tr><tr><td>LDL-C</td><td><italic>n</italic>&#x02009;=&#x02009;116</td><td><italic>n</italic>&#x02009;=&#x02009;66</td><td><italic>n</italic>&#x02009;=&#x02009;69</td><td><italic>n</italic>&#x02009;=&#x02009;49</td><td><italic>n</italic>&#x02009;=&#x02009;46</td><td><italic>n</italic>&#x02009;=&#x02009;51</td><td><italic>n</italic>&#x02009;=&#x02009;47</td></tr><tr><td>&#x000a0;&#x000a0;Baseline mean, mg/dL</td><td>154.4</td><td>147.9</td><td>146.6</td><td>147.2</td><td>143.9</td><td>151.9</td><td>152.9</td></tr><tr><td>&#x000a0;&#x000a0;Final mean, mg/dL</td><td>142.1</td><td>102.4</td><td>95.7</td><td>83.9</td><td>91.3</td><td>81.6</td><td>91.9</td></tr><tr><td>&#x000a0;&#x000a0;Mean change, % (SE)</td><td>&#x02212;5.2 (1.67)</td><td>&#x02212;28.1 (2.22)</td><td>&#x02212;32.8 (2.17)</td><td>&#x02212;43.3 (2.57)</td><td>&#x02212;36.8 (2.67)</td><td>&#x02212;44.3 (2.52)</td><td>&#x02212;37.0 (2.63)</td></tr><tr><td>&#x000a0;&#x000a0;<italic>P</italic>-value<sup>a</sup></td><td/><td/><td>&#x0003c;0.001<sup>d</sup></td><td/><td>&#x0003c;0.001<sup>d</sup></td><td/><td>&#x0003c;0.001<sup>d</sup></td></tr><tr><td>Non-HDL-C</td><td><italic>n</italic>&#x02009;=&#x02009;114</td><td><italic>n</italic>&#x02009;=&#x02009;66</td><td><italic>n</italic>&#x02009;=&#x02009;69</td><td><italic>n</italic>&#x02009;=&#x02009;46</td><td><italic>n</italic>&#x02009;=&#x02009;45</td><td><italic>n</italic>&#x02009;=&#x02009;49</td><td><italic>n</italic>&#x02009;=&#x02009;46</td></tr><tr><td>&#x000a0;&#x000a0;Baseline mean, mg/dL</td><td>218.2</td><td>217.8</td><td>218.3</td><td>217.4</td><td>213.9</td><td>222.5</td><td>216.3</td></tr><tr><td>&#x000a0;&#x000a0;Final mean, mg/dL</td><td>178.3</td><td>144.6</td><td>124.9</td><td>121.8</td><td>120.7</td><td>118.5</td><td>117.0</td></tr><tr><td>&#x000a0;&#x000a0;Mean change, % (SE)</td><td>&#x02212;17.5 (1.41)</td><td>&#x02212;33.5 (1.86)</td><td>&#x02212;41.1 (1.82)</td><td>&#x02212;44.6 (2.22)</td><td>&#x02212;43.6 (2.26)</td><td>&#x02212;45.8 (2.16)</td><td>&#x02212;44.9 (2.23)</td></tr><tr><td>&#x000a0;&#x000a0;<italic>P</italic>-value<sup>a</sup></td><td/><td/><td>&#x0003c;0.001<sup>d</sup></td><td/><td>&#x0003c;0.001<sup>d</sup></td><td/><td>&#x0003c;0.001<sup>d</sup></td></tr><tr><td/><td/><td/><td>0.004<sup>c</sup></td><td/><td>0.77<sup>c</sup></td><td/><td>0.77<sup>c</sup></td></tr><tr><td>ApoB</td><td><italic>n</italic>&#x02009;=&#x02009;116</td><td><italic>n</italic>&#x02009;=&#x02009;66</td><td><italic>n</italic>&#x02009;=&#x02009;69</td><td><italic>n</italic>&#x02009;=&#x02009;49</td><td><italic>n</italic>&#x02009;=&#x02009;50</td><td><italic>n</italic>&#x02009;=&#x02009;52</td><td><italic>n</italic>&#x02009;=&#x02009;50</td></tr><tr><td>&#x000a0;&#x000a0;Baseline mean, mg/dL</td><td>138.8</td><td>133.7</td><td>131.5</td><td>144.7</td><td>141.2</td><td>146.1</td><td>142.9</td></tr><tr><td>&#x000a0;&#x000a0;Final mean, mg/dL</td><td>117.9</td><td>97.7</td><td>86.6</td><td>90.3</td><td>88.6</td><td>88.7</td><td>87.8</td></tr><tr><td>&#x000a0;&#x000a0;Mean change, % (SE)</td><td>&#x02212;14.8 (1.37)</td><td>&#x02212;28.1 (1.82)</td><td>&#x02212;34.9 (1.79)</td><td>&#x02212;36.3 (2.11)</td><td>&#x02212;36.2 (2.09)</td><td>&#x02212;37.2 (2.05)</td><td>&#x02212;36.2 (2.08)</td></tr><tr><td>&#x000a0;&#x000a0;<italic>P</italic>-value<sup>a</sup></td><td/><td/><td>0.008<sup>c</sup></td><td/><td>0.97<sup>c</sup></td><td/><td>0.75<sup>c</sup></td></tr><tr><td>hsCRP</td><td><italic>n</italic>&#x02009;=&#x02009;117</td><td><italic>n</italic>&#x02009;=&#x02009;66</td><td><italic>n</italic>&#x02009;=&#x02009;69</td><td><italic>n</italic>&#x02009;=&#x02009;49</td><td><italic>n</italic>&#x02009;=&#x02009;50</td><td><italic>n</italic>&#x02009;=&#x02009;52</td><td><italic>n</italic>&#x02009;=&#x02009;50</td></tr><tr><td>&#x000a0;&#x000a0;Baseline median, mg/L</td><td>2.88</td><td>3.50</td><td>3.43</td><td>3.90</td><td>3.94</td><td>3.24</td><td>3.96</td></tr><tr><td>&#x000a0;&#x000a0;Final median, mg/L</td><td>2.62</td><td>2.82</td><td>2.37</td><td>2.42</td><td>2.71</td><td>2.14</td><td>2.55</td></tr><tr><td>&#x000a0;&#x000a0;Median change, %</td><td>&#x02212;7.2</td><td>&#x02212;11.5</td><td>&#x02212;26.8</td><td>&#x02212;31.1</td><td>&#x02212;28.0</td><td>&#x02212;34.2</td><td>&#x02212;40.7</td></tr><tr><td>&#x000a0;&#x000a0;<italic>P</italic>-value<sup>b</sup></td><td/><td/><td>0.20<sup>c</sup></td><td/><td>0.52<sup>c</sup></td><td/><td>0.99<sup>c</sup></td></tr></tbody></table><table-wrap-foot><p><italic>FA</italic> fenofibric acid; <italic>R</italic> rosuvastatin; <italic>HDL-C</italic> high-density lipoprotein cholesterol; <italic>LDL-C</italic> low-density lipoprotein cholesterol; <italic>TG</italic> triglycerides; <italic>ApoB</italic> apolipoprotein B; <italic>hsCRP</italic> high-sensitivity C-reactive protein. Only patients with both baseline and at least one postbaseline value were included in this analysis.</p><p><sup>a</sup><italic>P</italic>-value is from an analysis of covariance with the corresponding baseline value as the covariate and with effects for treatment group and screening TG level (&#x02264;250&#x000a0;mg/dL, &#x0003e;250&#x000a0;mg/dL).</p><p><sup>b</sup><italic>P</italic>-value is from the van Elteren&#x02019;s test with screening TG level as stratum.</p><p><sup>c</sup><italic>P</italic>-value for difference between R + FA group and corresponding-dose R monotherapy group.</p><p><sup>d</sup><italic>P</italic>-value for difference between R + FA group and FA monotherapy group.</p></table-wrap-foot></table-wrap></p><p>The safety profile of combination therapy with R + FA was consistent with the profiles of the individual monotherapies, and there were no unexpected adverse effects. Adverse events (AEs) were the most frequent reason cited for discontinuation in all groups. The incidence of discontinuations attributed to AEs was higher with combination therapy than with FA monotherapy or corresponding dose R monotherapy (Fig.&#x000a0;<xref rid="Fig1" ref-type="fig">1</xref>). The incidence of myalgia was similar across treatment groups, rhabdomyolysis was not reported, and elevations in creatine phosphokinase were observed infrequently in this cohort (Table&#x000a0;<xref rid="Tab3" ref-type="table">3</xref>). Hepatic-related AEs or laboratory abnormalities were rare. Increased creatinine levels were observed primarily with FA monotherapy and combination therapy (R 10 or 20&#x000a0;mg + FA; Table&#x000a0;<xref rid="Tab3" ref-type="table">3</xref>). Adverse events consistent with hyperglycemia or increased hemoglobin A1c were reported infrequently across all treatment groups.
<table-wrap id="Tab3"><label>Table&#x000a0;3</label><caption><p>Adverse events and laboratory variables related to muscle, hepatic, and renal function</p></caption><table frame="hsides" rules="groups"><thead><tr><th>Adverse events and laboratory variables</th><th>FA 135&#x000a0;mg (<italic>n</italic>&#x02009;=&#x02009;123)</th><th>R 5&#x000a0;mg (<italic>n</italic>&#x02009;=&#x02009;68)</th><th>R 5&#x000a0;mg + FA (<italic>n</italic>&#x02009;=&#x02009;73)</th><th>R 10&#x000a0;mg (<italic>n</italic>&#x02009;=&#x02009;52)</th><th>R 10&#x000a0;mg + FA (<italic>n</italic>&#x02009;=&#x02009;52)</th><th>R 20&#x000a0;mg (<italic>n</italic>&#x02009;=&#x02009;53)</th><th>R 20&#x000a0;mg + FA (<italic>n</italic>&#x02009;=&#x02009;52)</th></tr></thead><tbody><tr><td colspan="8">Muscle-related</td></tr><tr><td>Myalgia, n (%)<sup>a</sup></td><td>3 (2.4)</td><td>2 (2.9)</td><td>1 (1.4)</td><td>3 (5.8)</td><td>1 (1.9)</td><td>1 (1.9)</td><td>2 (3.8)</td></tr><tr><td>CK increased, n (%)<sup>a</sup></td><td>4 (3.3)</td><td>0</td><td>2 (2.7)</td><td>1 (1.9)</td><td>0</td><td>2 (3.8)</td><td>0</td></tr><tr><td>CK &#x0003e;5&#x000d7; ULN, n/N (%)</td><td>0/119</td><td>0/68</td><td>0/71</td><td>0/50</td><td>1/51 (2.0)</td><td>0/53</td><td>0/51</td></tr><tr><td>CK &#x0003e;10&#x000d7; ULN, n/N (%)</td><td>0/119</td><td>0/68</td><td>0/71</td><td>0/50</td><td>1/51 (2.0)</td><td>0/53</td><td>0/51</td></tr><tr><td colspan="8">Hepatic-related</td></tr><tr><td>ALT &#x0003e;5&#x000d7; ULN, n/N (%)</td><td>0/119</td><td>0/68</td><td>1/71 (1.4)</td><td>0/50</td><td>0/50</td><td>0/53</td><td>0/51</td></tr><tr><td colspan="8">Renal-related</td></tr><tr><td>Creatinine increased, n (%)<sup>a</sup></td><td>3 (2.4)</td><td>0</td><td>0</td><td>0</td><td>1 (1.9)</td><td>0</td><td>3 (5.8)</td></tr><tr><td>Creatinine &#x02265;50% increase from baseline and &#x0003e;ULN, n/N (%)</td><td>12/119 (10.1)</td><td>0/68</td><td>1/71 (1.4)<sup>b</sup></td><td>2/50 (4.0)</td><td>2/50 (4.0)</td><td>0/53</td><td>2/51 (3.9)</td></tr><tr><td>Creatinine &#x02265;100% increase from baseline, n/N (%)</td><td>1/119 (0.8)</td><td>0/68</td><td>0/71</td><td>0/50</td><td>0/50</td><td>0/53</td><td>0/51</td></tr><tr><td>Creatinine &#x0003e;2&#x000a0;mg/dL, n/N (%)</td><td>8/119 (6.7)</td><td>0/68</td><td>0/71<sup>b</sup></td><td>1/50 (2.0)</td><td>2/50 (4.0)</td><td>0/53</td><td>1/51 (2.0)</td></tr></tbody></table><table-wrap-foot><p><italic>FA</italic> fenofibric acid; <italic>R</italic> rosuvastatin; <italic>CK</italic> creatine phosphokinase; <italic>ULN</italic> upper limit of normal; <italic>ALT</italic> alanine aminotransferase; <italic>MedDRA</italic> Medical Dictionary for Regulatory Activities.</p><p><sup>a</sup>MedDRA Version 11.1 preferred term.</p><p><sup>b</sup><italic>P</italic>&#x02009;&#x0003c;&#x02009;0.05 for comparison between R + FA group and FA monotherapy group using Fisher&#x02019;s exact text.</p></table-wrap-foot></table-wrap></p></sec><sec id="Sec7"><title>Discussion</title><p>This post hoc analysis was performed on pooled data for the subset of patients with T2DM from two phase 3 studies that evaluated the lipid-altering efficacy and safety of R + FA combination therapy in patients with mixed dyslipidemia. The primary objective of this analysis was to evaluate the achievement of individual and combined lipid targets. In this analysis, a significantly higher proportion of patients achieved individual targets for HDL-C with R 10&#x000a0;mg + FA, TG with R 10 or 20&#x000a0;mg + FA, non-HDL-C with R 5&#x000a0;mg + FA, and ApoB with R 5&#x000a0;mg + FA, compared with corresponding-dose R monotherapies. The proportion of patients who achieved the combined target of two lipid parameters (LDL-C and non-HDL-C) was greater with the combinations of R 5&#x000a0;mg + FA and R 20&#x000a0;mg + FA than with the corresponding-dose R monotherapies; these differences were not statistically significant. The proportion of patients who achieved the combined target of three lipid parameters (LDL-C, HDL-C, and TG) and five lipid parameters (LDL-C, HDL-C, TG, non-HDL-C, and ApoB) was 3-fold greater and statistically significant with R 10&#x000a0;mg + FA versus R 10&#x000a0;mg; R 10&#x000a0;mg + FA had the highest incidence of patients attaining the combined target of three and five parameters compared with R 10&#x000a0;mg (28.3% vs. 8.3% for three parameters and 26.1% vs. 8.3% for five parameters). It is noted that a dose-related increase in the proportion of patients achieving the combined target of three and five parameters was not observed with the combination of R 20&#x000a0;mg + FA, compared with R 10&#x000a0;mg + FA. The reason for this is unclear, but may be related to the severity of hypertriglyceridemia in the patients of this study. Nonetheless, the R 20&#x000a0;mg + FA combination may be required for patients in clinical practice who require a higher statin dose in order to reach their individual LDL-C target, in addition to fibrate therapy to treat HDL-C and TG abnormalities. In a separate study of the fixed-dose combination of rosuvastatin and fenofibric acid in patients with elevated LDL-C but more modestly elevated TG, a numerically greater proportion of patients achieved the combined target of five parameters with rosuvastatin/fenofibric acid 20&#x000a0;mg/135&#x000a0;mg versus 10&#x000a0;mg/135&#x000a0;mg (50.9% vs. 45.1%) [<xref ref-type="bibr" rid="CR14">14</xref>].</p><p>Because T2DM is designated as a CHD risk equivalent in the NCEP ATP III guidelines, the primary treatment goal in patients with T2DM is LDL-C &#x0003c;100&#x000a0;mg/dL. As noted earlier, guidelines suggest treating other lipid components in addition to LDL-C to reduce the overall risk of CVD. Patients with T2DM frequently present with mixed dyslipidemia, which is characterized by abnormalities in LDL particle size, low levels of HDL-C, and elevated levels of TG. In this patient population, ApoB and LDL particle concentration more accurately define residual CVD risk and are stronger predictors of cardiovascular outcome than LDL-C [<xref ref-type="bibr" rid="CR15">15</xref>]. In both Study 1 and Study 2, FA, a fibrate that effectively raises HDL-C and lowers TG, in combination with R, improved multiple lipid parameters in patients with mixed dyslipidemia [<xref ref-type="bibr" rid="CR10">10</xref>, <xref ref-type="bibr" rid="CR11">11</xref>].</p><p>The achievement of LDL-C goals has been evaluated in clinical trials of statin monotherapy and combination therapy [<xref ref-type="bibr" rid="CR16">16</xref>&#x02013;<xref ref-type="bibr" rid="CR23">23</xref>]. In studies in which R was used, given its efficacy, approximately 80% or more of patients treated with R monotherapy or combination therapy achieved LDL-C goals [<xref ref-type="bibr" rid="CR16">16</xref>, <xref ref-type="bibr" rid="CR18">18</xref>, <xref ref-type="bibr" rid="CR19">19</xref>, <xref ref-type="bibr" rid="CR21">21</xref>&#x02013;<xref ref-type="bibr" rid="CR23">23</xref>]. In CORALL, a study that evaluated LDL-C goal attainment in patients with T2DM, 82% and 84% of patients treated with R 10 and 20&#x000a0;mg, respectively, achieved the LDL-C goal of &#x0003c;100&#x000a0;mg/dL at 24&#x000a0;weeks of treatment [<xref ref-type="bibr" rid="CR23">23</xref>]. Although there were differences in study design and duration of treatment, the goal attainment results of the CORALL study are similar to the proportion of patients who achieved LDL-C goals with R 10 and 20&#x000a0;mg monotherapy in the present analysis. The proportions of T2DM patients who achieved the LDL-C goal of &#x0003c;100&#x000a0;mg/dL in the present studies with R + FA combination therapy were slightly lower than the proportions who achieved this goal with corresponding-dose R monotherapies. This is not surprising, because it has been shown that treatment with fibrates results in either a small increase or no change in the measured LDL-C content in patients with high TG and low HDL-C levels, likely because of accelerated fibrate-induced catabolism of TG-rich very-low-density lipoprotein (VLDL) particles [<xref ref-type="bibr" rid="CR24">24</xref>&#x02013;<xref ref-type="bibr" rid="CR26">26</xref>]. Treatment with fibrates also results in a shift in LDL particle size from a small and dense to a larger phenotype [<xref ref-type="bibr" rid="CR27">27</xref>&#x02013;<xref ref-type="bibr" rid="CR29">29</xref>].</p><p>Attainment of the LDL-C goal is just one component of the recommended lipid profile for patients with T2DM. In order to reduce CVD risk, these patients must also increase HDL-C levels and decrease TG levels [<xref ref-type="bibr" rid="CR30">30</xref>&#x02013;<xref ref-type="bibr" rid="CR33">33</xref>]. In this analysis of the two controlled studies, patients with T2DM showed significantly greater mean percent changes in LDL-C, HDL-C, TG, non-HDL-C, and ApoB with R 5&#x000a0;mg + FA; LDL-C, HDL-C, and TG with R 10&#x000a0;mg + FA; and LDL-C and TG with R 20&#x000a0;mg + FA, compared with prespecified monotherapies.</p><p>The results of this analysis are supported by the findings reported in a study comparing the efficacy of R 5 or 10&#x000a0;mg + fenofibrate combination therapy with that of each monotherapy component in patients with T2DM who had high levels of TG and total cholesterol at baseline [<xref ref-type="bibr" rid="CR34">34</xref>]. In that study, decreases in TG levels of 34% and 30% and changes in LDL-C of +1% and &#x02212;47% were achieved after 24&#x000a0;weeks of treatment with fenofibrate monotherapy and R monotherapy, respectively. Administration of R 10&#x000a0;mg + fenofibrate resulted in a 47% decrease in TG, which was significantly greater (<italic>P</italic>&#x02009;=&#x02009;0.001) than that seen with R monotherapy.</p><p>The ACCORD (Action to Control Cardiovascular Risk in Diabetes) Lipid component of the overall ACCORD trial was designed to test whether CVD event reduction with the combination of a statin and a fibrate would exceed what is achieved with statin monotherapy in patients with T2DM. It should be noted that although the combination of simvastatin and fenofibrate in the ACCORD Lipid study did not significantly reduce the rate of nonfatal myocardial infarction, nonfatal stroke, or cardiovascular death compared with simvastatin alone, a prespecified analysis demonstrated in patients with both high TG (&#x02265;204&#x000a0;mg/dL) and low HDL-C (&#x02264;34&#x000a0;mg/dL) a 31% relative risk reduction in cardiovascular events with combination therapy compared with the monotherapy group [<xref ref-type="bibr" rid="CR35">35</xref>]. Furthermore, the ACCORD Eye study, which evaluated the progression of diabetic retinopathy in a subgroup of patients from the ACCORD study found that treatment with simvastatin and fenofibrate resulted in a significant 40% reduction in the progression of diabetic retinopathy versus simvastatin monotherapy [<xref ref-type="bibr" rid="CR36">36</xref>].</p><p>Combination therapy with R + FA was generally well tolerated in the subgroup of patients with T2DM. The safety profile of R + FA combination therapy was consistent with that of each monotherapy. Although, the risk for increased muscle-related AEs is a safety concern when combining fibrates with statins, the incidence of myalgia was lower with R 5 or 10&#x000a0;mg + FA, compared with the corresponding-dose R monotherapy, and there were no reports of rhabdomyolysis in this analysis. Similarly, the ACCORD Lipid study found no increased risk for muscle-related AEs with simvastatin and fenofibrate combination treatment for up to 4.5&#x000a0;years compared with simvastatin alone [<xref ref-type="bibr" rid="CR35">35</xref>]. Elevations in liver enzymes were infrequent occurrences in the present analysis and abnormal creatinine values were observed predominantly with FA monotherapy and combination therapy.</p><p>The major limitations for application of these results to clinical practice are attributable to constraints of study design. Combination therapy with R + FA was initiated in the studies that provided data for this analysis, whereas in clinical practice statin monotherapy is often initiated first with FA added to the regimen if treatment goals are not met or if further titration of the statin is contraindicated. Although the duration of treatment, which was limited to 12&#x000a0;weeks in these studies, was sufficient to demonstrate efficacy, it probably is not an accurate reflection of full treatment effect in clinical practice. The results of a long-term clinical trial in which patients with mixed dyslipidemia, who completed Study 2, received R 20&#x000a0;mg + FA for 52&#x000a0;weeks confirmed additional benefit with a longer duration of combination treatment [<xref ref-type="bibr" rid="CR37">37</xref>].</p><p>Despite these limitations, this analysis clearly demonstrated the effectiveness and safety of R + FA combination therapy in attaining individual and combined lipid targets in patients with T2DM, compared with R monotherapy.</p></sec></body><back><ack><p>We thank all investigators, study coordinators, and patients who participated in the study. Hsiaoming Sun, Min Tian, and Aditya Lele, of Abbott provided assistance with statistical analyses; Noreen Travers, and Lura Morris, of Abbott provided assistance with clinical study management. Geeta Thakker and Darryl Sleep provided medical writing assistance on behalf of Abbott. Rachelle Weiss, of Ledell Group, provided medical writing support for this paper and was compensated by Abbott for this support.</p><p>Robert S. Rosenson is a consultant for Abbott; serves on the speaker&#x02019;s bureau for AstraZeneca; serves on the scientific advisory board for Residual Risk Reduction Initiative and has received honorarium from Residual Risk Reduction Initiative. Dawn Carlson, Maureen Kelly, Carolyn Setze, James Stolzenbach, and Laura Williams are employees of Abbott. Boaz Hirshberg is an employee of AstraZeneca. Abbott and AstraZeneca sponsored the studies.</p><p><bold>Open Access</bold> This article is distributed under the terms of the Creative Commons Attribution Noncommercial License which permits any noncommercial use, distribution, and reproduction in any medium, provided the original author(s) and source are credited.</p></ack><ref-list id="Bib1"><title>References</title><ref id="CR1"><label>1.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Steiner</surname><given-names>G</given-names></name></person-group><article-title>Treating lipid abnormalities in patients with type 2 diabetes mellitus</article-title><source>Am J Cardiol</source><year>2001</year><volume>88</volume><issue>suppl</issue><fpage>37N</fpage><lpage>40N</lpage><pub-id pub-id-type="doi">10.1016/S0002-9149(01)02151-8</pub-id><pub-id pub-id-type="pmid">11788129</pub-id></mixed-citation></ref><ref id="CR2"><label>2.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kendall</surname><given-names>DM</given-names></name></person-group><article-title>The dyslipidemia of diabetes mellitus: giving triglycerides and high-density lipoprotein cholesterol a higher priority?</article-title><source>Endocrinol Metab Clin N Am</source><year>2005</year><volume>34</volume><fpage>27</fpage><lpage>48</lpage><pub-id pub-id-type="doi">10.1016/j.ecl.2004.11.004</pub-id></mixed-citation></ref><ref id="CR3"><label>3.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Brunzell</surname><given-names>JD</given-names></name><name><surname>Davidson</surname><given-names>M</given-names></name><name><surname>Furburg</surname><given-names>CD</given-names></name><name><surname>Goldberg</surname><given-names>RB</given-names></name><name><surname>Howard</surname><given-names>BV</given-names></name><name><surname>Stein</surname><given-names>JH</given-names></name><etal/></person-group><article-title>Lipoprotein management in patients with cardiometabolic risk. Consensus statement from the American Diabetes Association and the American College of Cardiology Foundation</article-title><source>Diabetes Care</source><year>2008</year><volume>31</volume><fpage>811</fpage><lpage>822</lpage><pub-id pub-id-type="doi">10.2337/dc08-9018</pub-id><pub-id pub-id-type="pmid">18375431</pub-id></mixed-citation></ref><ref id="CR4"><label>4.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rosenson</surname><given-names>RS</given-names></name><name><surname>Otvos</surname><given-names>JD</given-names></name><name><surname>Hsia</surname><given-names>J</given-names></name></person-group><article-title>Effects of rosuvastatin and atorvastatin on LDL and HDL particle concentrations in patients with metabolic syndrome</article-title><source>Diabetes Care</source><year>2009</year><volume>32</volume><fpage>1087</fpage><lpage>1091</lpage><pub-id pub-id-type="doi">10.2337/dc08-1681</pub-id><pub-id pub-id-type="pmid">19265025</pub-id></mixed-citation></ref><ref id="CR5"><label>5.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Garvey</surname><given-names>WT</given-names></name><name><surname>Kwon</surname><given-names>S</given-names></name><name><surname>Zheng</surname><given-names>D</given-names></name><name><surname>Shaughnessy</surname><given-names>S</given-names></name><name><surname>Wallace</surname><given-names>P</given-names></name><name><surname>Hutto</surname><given-names>A</given-names></name><etal/></person-group><article-title>Effects of insulin resistance and type 2 diabetes on lipoprotein subclass particle size and concentration determined by nuclear magnetic resonance</article-title><source>Diabetes</source><year>2003</year><volume>52</volume><fpage>453</fpage><lpage>462</lpage><pub-id pub-id-type="doi">10.2337/diabetes.52.2.453</pub-id><pub-id pub-id-type="pmid">12540621</pub-id></mixed-citation></ref><ref id="CR6"><label>6.</label><mixed-citation publication-type="other">Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation. 2002;106:3143&#x02013;3421.</mixed-citation></ref><ref id="CR7"><label>7.</label><mixed-citation publication-type="other">American Diabetes Association 2009 Executive summary: Standards of medical care in diabetes&#x02013;2009. Diabetes Care. 2009;32(Suppl 1):S6&#x02013;S12.</mixed-citation></ref><ref id="CR8"><label>8.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Grundy</surname><given-names>SM</given-names></name><name><surname>Cleeman</surname><given-names>JI</given-names></name><name><surname>Merz</surname><given-names>CNB</given-names></name><name><surname>Brewer</surname><given-names>HB</given-names><suffix>Jr</suffix></name><name><surname>Clark</surname><given-names>LT</given-names></name><name><surname>Hunninghake</surname><given-names>DB</given-names></name><etal/></person-group><article-title>Coordinating Committee of the National Cholesterol Education Program. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines</article-title><source>Circulation</source><year>2004</year><volume>110</volume><fpage>227</fpage><lpage>239</lpage><pub-id pub-id-type="doi">10.1161/01.CIR.0000133317.49796.0E</pub-id><pub-id pub-id-type="pmid">15249516</pub-id></mixed-citation></ref><ref id="CR9"><label>9.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fruchart</surname><given-names>JC</given-names></name><name><surname>Sacks</surname><given-names>FM</given-names></name><name><surname>Hermans</surname><given-names>MP</given-names></name><name><surname>Assmann</surname><given-names>G</given-names></name><name><surname>Brown</surname><given-names>WV</given-names></name><name><surname>Ceska</surname><given-names>R</given-names></name><etal/></person-group><article-title>The residual risk reduction initiative: a call to action to reduce residual vascular risk in dyslipidaemic patient</article-title><source>Diab Vasc Dis Res</source><year>2008</year><volume>5</volume><fpage>319</fpage><lpage>335</lpage><pub-id pub-id-type="doi">10.3132/dvdr.2008.046</pub-id><pub-id pub-id-type="pmid">18958843</pub-id></mixed-citation></ref><ref id="CR10"><label>10.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Roth</surname><given-names>EM</given-names></name><name><surname>Rosenson</surname><given-names>RS</given-names></name><name><surname>Carlson</surname><given-names>DM</given-names></name><name><surname>Fukumoto</surname><given-names>SM</given-names></name><name><surname>Setze</surname><given-names>CM</given-names></name><name><surname>Blasetto</surname><given-names>JW</given-names></name><etal/></person-group><article-title>Efficacy and safety of rosuvastatin 5&#x000a0;mg in combination with fenofibric acid 135&#x000a0;mg in patients with mixed dyslipidemia&#x02014;A phase 3 study</article-title><source>Cardiovasc Drugs Ther</source><year>2010</year><pub-id pub-id-type="pmid">20953684</pub-id></mixed-citation></ref><ref id="CR11"><label>11.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jones</surname><given-names>PH</given-names></name><name><surname>Davidson</surname><given-names>MH</given-names></name><name><surname>Kashyap</surname><given-names>ML</given-names></name><name><surname>Kelly</surname><given-names>MT</given-names></name><name><surname>Buttler</surname><given-names>SM</given-names></name><name><surname>Setze</surname><given-names>CM</given-names></name><etal/></person-group><article-title>Efficacy and safety of ABT-335 (fenofibric acid) in combination with rosuvastatin in patients with mixed dyslipidemia: a phase 3 study</article-title><source>Atherosclerosis</source><year>2009</year><volume>204</volume><fpage>208</fpage><lpage>215</lpage><pub-id pub-id-type="doi">10.1016/j.atherosclerosis.2008.09.027</pub-id><pub-id pub-id-type="pmid">18996523</pub-id></mixed-citation></ref><ref id="CR12"><label>12.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jones</surname><given-names>PH</given-names></name><name><surname>Bays</surname><given-names>HE</given-names></name><name><surname>Davidson</surname><given-names>MH</given-names></name><name><surname>Kelly</surname><given-names>MT</given-names></name><name><surname>Buttler</surname><given-names>SM</given-names></name><name><surname>Setze</surname><given-names>CM</given-names></name><etal/></person-group><article-title>Evaluation of a new formulation of fenofibric acid, ABT-335, co-administered with statins: study design and rationale of a phase III clinical programme</article-title><source>Clin Drug Investig</source><year>2008</year><volume>28</volume><fpage>625</fpage><lpage>634</lpage><pub-id pub-id-type="doi">10.2165/00044011-200828100-00003</pub-id><pub-id pub-id-type="pmid">18783301</pub-id></mixed-citation></ref><ref id="CR13"><label>13.</label><mixed-citation publication-type="other">American Heart Association. An eating plan for healthy Americans&#x02014;our American Heart Association diet. Dallas (TX): AHA, 2004. AHA Publication No. 50-1481A.</mixed-citation></ref><ref id="CR14"><label>14.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Roth</surname><given-names>EM</given-names></name><name><surname>McKenney</surname><given-names>JM</given-names></name><name><surname>Kelly</surname><given-names>MT</given-names></name><name><surname>Setze</surname><given-names>CM</given-names></name><name><surname>Carlson</surname><given-names>DM</given-names></name><name><surname>Gold</surname><given-names>A</given-names></name><etal/></person-group><article-title>Efficacy and safety of rosuvastatin and fenofibric acid combination therapy versus simvastatin monotherapy in patients with hypercholesterolemia and hypertriglyceridemia: a randomized, double-blind study</article-title><source>Am J Cardiovasc Drugs</source><year>2010</year><volume>10</volume><fpage>175</fpage><lpage>186</lpage><pub-id pub-id-type="doi">10.2165/11533430-000000000-00000</pub-id><pub-id pub-id-type="pmid">20524719</pub-id></mixed-citation></ref><ref id="CR15"><label>15.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rosenson</surname><given-names>RS</given-names></name><name><surname>Davidson</surname><given-names>MH</given-names></name><name><surname>Pourfarzib</surname><given-names>R</given-names></name></person-group><article-title>Underappreciated opportunities for low-density lipoprotein management in patients with cardiometabolic residual risk</article-title><source>Atherosclerosis</source><year>2010</year><pub-id pub-id-type="pmid">20451205</pub-id></mixed-citation></ref><ref id="CR16"><label>16.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Berne</surname><given-names>C</given-names></name><name><surname>Siewert-Delle</surname><given-names>A</given-names></name></person-group><article-title>URANUS study investigators. Comparison of rosuvastatin and atorvastatin for lipid lowering in patients with type 2 diabetes mellitus: results from the URANUS study</article-title><source>Cardiovasc Diabetol</source><year>2005</year><volume>4</volume><fpage>7</fpage><pub-id pub-id-type="doi">10.1186/1475-2840-4-7</pub-id><pub-id pub-id-type="pmid">15935095</pub-id></mixed-citation></ref><ref id="CR17"><label>17.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ballantyne</surname><given-names>CM</given-names></name><name><surname>Abate</surname><given-names>N</given-names></name><name><surname>Yuan</surname><given-names>Z</given-names></name><name><surname>King</surname><given-names>TR</given-names></name><name><surname>Palmisano</surname><given-names>J</given-names></name></person-group><article-title>Dose-comparison study of the combination of ezetimibe and simvastatin (Vytorin) versus atorvastatin in patients with hypercholesterolemia: the Vytorin versus atorvastatin (VYVA) study</article-title><source>Am Heart J</source><year>2004</year><volume>149</volume><fpage>464</fpage><lpage>473</lpage><pub-id pub-id-type="doi">10.1016/j.ahj.2004.11.023</pub-id><pub-id pub-id-type="pmid">15864235</pub-id></mixed-citation></ref><ref id="CR18"><label>18.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Davidson</surname><given-names>MH</given-names></name><name><surname>Ballantyne</surname><given-names>CM</given-names></name><name><surname>Kerzner</surname><given-names>B</given-names></name><name><surname>Melani</surname><given-names>L</given-names></name><name><surname>Sager</surname><given-names>PT</given-names></name><name><surname>Lipka</surname><given-names>L</given-names></name><collab>Ezetimibe Study Group</collab><etal/></person-group><article-title>Efficacy and safety of ezetimibe coadministered with statins: randomised, placebo-controlled, blinded experience in 2382 patients with primary hypercholesterolemia</article-title><source>Int J Clin Pract</source><year>2005</year><volume>58</volume><fpage>746</fpage><lpage>755</lpage><pub-id pub-id-type="doi">10.1111/j.1368-5031.2004.00289.x</pub-id><pub-id pub-id-type="pmid">15372846</pub-id></mixed-citation></ref><ref id="CR19"><label>19.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jones</surname><given-names>PH</given-names></name><name><surname>Davidson</surname><given-names>MH</given-names></name><name><surname>Stein</surname><given-names>EA</given-names></name><name><surname>Bays</surname><given-names>HE</given-names></name><name><surname>McKenney</surname><given-names>JM</given-names></name><name><surname>Miller</surname><given-names>E</given-names></name><collab>STELLAR Study Group</collab><etal/></person-group><article-title>Comparison of the efficacy and safety of rosuvastatin versus atorvastatin, simvastatin, and pravastatin across doses (STELLAR* trial)</article-title><source>Am J Cardiol</source><year>2003</year><volume>92</volume><fpage>152</fpage><lpage>160</lpage><pub-id pub-id-type="doi">10.1016/S0002-9149(03)00530-7</pub-id><pub-id pub-id-type="pmid">12860216</pub-id></mixed-citation></ref><ref id="CR20"><label>20.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>McKenney</surname><given-names>J</given-names></name><name><surname>Ballantyne</surname><given-names>CM</given-names></name><name><surname>Feldman</surname><given-names>TA</given-names></name><name><surname>Brady</surname><given-names>WE</given-names></name><name><surname>Shah</surname><given-names>A</given-names></name><name><surname>Davies</surname><given-names>MJ</given-names></name><etal/></person-group><article-title>LDL-C goal attainment with ezetimibe plus simvastatin coadministration vs atorvastatin or simvastatin monotherapy in patients at high risk of CHD</article-title><source>MedGenMed</source><year>2005</year><volume>7</volume><fpage>3</fpage><pub-id pub-id-type="pmid">16369229</pub-id></mixed-citation></ref><ref id="CR21"><label>21.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>McKenney</surname><given-names>JM</given-names></name><name><surname>Jones</surname><given-names>PH</given-names></name><name><surname>Angeli Adamczyk</surname><given-names>M</given-names></name><name><surname>Cain</surname><given-names>VA</given-names></name><name><surname>Bryzinski</surname><given-names>BS</given-names></name><collab>STELLAR Study Group</collab><etal/></person-group><article-title>Comparison of the efficacy of rosuvastatin versus atorvastatin, simvastatin, and pravastatin in achieving lipid goals: results from the STELLAR trial</article-title><source>Curr Med Res Opin</source><year>2003</year><volume>19</volume><fpage>689</fpage><lpage>698</lpage><pub-id pub-id-type="doi">10.1185/030079903125002405</pub-id><pub-id pub-id-type="pmid">14687438</pub-id></mixed-citation></ref><ref id="CR22"><label>22.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Stalenhoef</surname><given-names>AFH</given-names></name><name><surname>Ballantye</surname><given-names>CM</given-names></name><name><surname>Sarti</surname><given-names>C</given-names></name><name><surname>Murin</surname><given-names>J</given-names></name><name><surname>Tonstad</surname><given-names>S</given-names></name><name><surname>Rose</surname><given-names>H</given-names></name><etal/></person-group><article-title>A COmparative study with rosuvastatin in subjects with METabolic Syndrome: results of the COMETS study</article-title><source>Eur Heart J</source><year>2005</year><volume>26</volume><fpage>2664</fpage><lpage>2672</lpage><pub-id pub-id-type="doi">10.1093/eurheartj/ehi482</pub-id><pub-id pub-id-type="pmid">16143705</pub-id></mixed-citation></ref><ref id="CR23"><label>23.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wolffenbuttel</surname><given-names>BHR</given-names></name><name><surname>Franken</surname><given-names>AAM</given-names></name><name><surname>Vincent</surname><given-names>HH</given-names></name><collab>Dutch CORALL Study Group</collab></person-group><article-title>Cholesterol-lowering effects of rosuvastatin compared with atorvastatin in patients with type 2 diabetes&#x02014;CORALL study</article-title><source>J Intern Med</source><year>2005</year><volume>257</volume><fpage>531</fpage><lpage>539</lpage><pub-id pub-id-type="doi">10.1111/j.1365-2796.2005.01499.x</pub-id><pub-id pub-id-type="pmid">15910557</pub-id></mixed-citation></ref><ref id="CR24"><label>24.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lemieux</surname><given-names>I</given-names></name><name><surname>Laperri&#x000e8;re</surname><given-names>L</given-names></name><name><surname>Dzavik</surname><given-names>V</given-names></name><name><surname>Tremblay</surname><given-names>G</given-names></name><name><surname>Bourgeois</surname><given-names>J</given-names></name><name><surname>Despr&#x000e9;s</surname><given-names>JP</given-names></name></person-group><article-title>A 16-week fenofibrate treatment increases LDL particle size in type IIA dyslipidemic patients</article-title><source>Atherosclerosis</source><year>2002</year><volume>162</volume><fpage>363</fpage><lpage>371</lpage><pub-id pub-id-type="doi">10.1016/S0021-9150(01)00711-0</pub-id><pub-id pub-id-type="pmid">11996956</pub-id></mixed-citation></ref><ref id="CR25"><label>25.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Elisaf</surname><given-names>M</given-names></name></person-group><article-title>Effects of fibrates on serum metabolic parameters</article-title><source>Curr Med Res Opin</source><year>2002</year><volume>18</volume><fpage>269</fpage><lpage>276</lpage><pub-id pub-id-type="doi">10.1185/030079902125000516</pub-id><pub-id pub-id-type="pmid">12240789</pub-id></mixed-citation></ref><ref id="CR26"><label>26.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rosenson</surname><given-names>RS</given-names></name><name><surname>Wolff</surname><given-names>DA</given-names></name><name><surname>Huskin</surname><given-names>AL</given-names></name><name><surname>Helenowski</surname><given-names>IB</given-names></name><name><surname>Rademaker</surname><given-names>AW</given-names></name></person-group><article-title>Fenofibrate therapy ameliorates fasting and postprandial lipoproteinemia, oxidative stress, and the inflammatory response in subjects with hypertriglyceridemia and the metabolic syndrome</article-title><source>Diabetes Care</source><year>2007</year><volume>30</volume><fpage>1945</fpage><lpage>1951</lpage><pub-id pub-id-type="doi">10.2337/dc07-0015</pub-id><pub-id pub-id-type="pmid">17483155</pub-id></mixed-citation></ref><ref id="CR27"><label>27.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Campos</surname><given-names>H</given-names></name><name><surname>Genest</surname><given-names>JJ</given-names><suffix>Jr</suffix></name><name><surname>Blijlevens</surname><given-names>E</given-names></name><name><surname>McNamara</surname><given-names>JR</given-names></name><name><surname>Jenner</surname><given-names>JL</given-names></name><name><surname>Ordovas</surname><given-names>JM</given-names></name><etal/></person-group><article-title>Low density lipoprotein particle size and coronary artery disease</article-title><source>Arterioscler Thromb</source><year>1992</year><volume>12</volume><fpage>187</fpage><lpage>195</lpage><pub-id pub-id-type="pmid">1543692</pub-id></mixed-citation></ref><ref id="CR28"><label>28.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Campos</surname><given-names>H</given-names></name><name><surname>Blijlevens</surname><given-names>E</given-names></name><name><surname>McNamara</surname><given-names>JR</given-names></name><name><surname>Ordovas</surname><given-names>JM</given-names></name><name><surname>Posner</surname><given-names>BM</given-names></name><name><surname>Wilson</surname><given-names>PW</given-names></name><etal/></person-group><article-title>LDL particle size distribution. Results from the Framingham Offspring Study</article-title><source>Arterioscler Thromb</source><year>1992</year><volume>12</volume><fpage>1410</fpage><lpage>1419</lpage><pub-id pub-id-type="pmid">1450174</pub-id></mixed-citation></ref><ref id="CR29"><label>29.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Griffin</surname><given-names>BA</given-names></name><name><surname>Freeman</surname><given-names>DJ</given-names></name><name><surname>Tait</surname><given-names>GW</given-names></name><name><surname>Thomson</surname><given-names>J</given-names></name><name><surname>Caslake</surname><given-names>MJ</given-names></name><name><surname>Packard</surname><given-names>CJ</given-names></name><etal/></person-group><article-title>Role of plasma triglyceride in the regulation of plasma low density lipoprotein (LDL) subfractions: relative contribution of small, dense LDL to coronary heart disease risk</article-title><source>Atherosclerosis</source><year>1994</year><volume>106</volume><fpage>241</fpage><lpage>253</lpage><pub-id pub-id-type="doi">10.1016/0021-9150(94)90129-5</pub-id><pub-id pub-id-type="pmid">8060384</pub-id></mixed-citation></ref><ref id="CR30"><label>30.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Assmann</surname><given-names>G</given-names></name><name><surname>Schulte</surname><given-names>H</given-names></name></person-group><article-title>Relation of high-density lipoprotein cholesterol and triglycerides to incidence of atherosclerotic coronary artery disease (the PROCAM experience). Prospective Cardiovascular Munster study</article-title><source>Am J Cardiol</source><year>1992</year><volume>70</volume><fpage>733</fpage><lpage>737</lpage><pub-id pub-id-type="doi">10.1016/0002-9149(92)90550-I</pub-id><pub-id pub-id-type="pmid">1519522</pub-id></mixed-citation></ref><ref id="CR31"><label>31.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Assmann</surname><given-names>G</given-names></name><name><surname>Schulte</surname><given-names>H</given-names></name><name><surname>Cullen</surname><given-names>P</given-names></name><name><surname>Seedorf</surname><given-names>U</given-names></name></person-group><article-title>Assessing risk of myocardial infarction and stroke: new data from the Prospective Cardiovascular Munster (PROCAM) study</article-title><source>Eur J Clin Invest</source><year>2007</year><volume>37</volume><fpage>925</fpage><lpage>932</lpage><pub-id pub-id-type="doi">10.1111/j.1365-2362.2007.01888.x</pub-id><pub-id pub-id-type="pmid">18036028</pub-id></mixed-citation></ref><ref id="CR32"><label>32.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hokanson</surname><given-names>JE</given-names></name><name><surname>Austin</surname><given-names>MA</given-names></name></person-group><article-title>Plasma triglyceride level is a risk factor for cardiovascular disease independent of high-density lipoprotein cholesterol level: a meta-analysis of population-based prospective studies</article-title><source>J Cardiovasc Risk</source><year>1996</year><volume>3</volume><fpage>213</fpage><lpage>219</lpage><pub-id pub-id-type="doi">10.1097/00043798-199604000-00014</pub-id><pub-id pub-id-type="pmid">8836866</pub-id></mixed-citation></ref><ref id="CR33"><label>33.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sarwar</surname><given-names>N</given-names></name><name><surname>Danesh</surname><given-names>J</given-names></name><name><surname>Eiriksdottir</surname><given-names>G</given-names></name><name><surname>Sigurdsson</surname><given-names>G</given-names></name><name><surname>Wareham</surname><given-names>N</given-names></name><name><surname>Bingham</surname><given-names>S</given-names></name><etal/></person-group><article-title>Triglycerides and the risk of coronary heart disease: 10, 158 incident cases among 262, 565 participants in 29 Western prospective studies</article-title><source>Circulation</source><year>2007</year><volume>115</volume><fpage>450</fpage><lpage>458</lpage><pub-id pub-id-type="doi">10.1161/CIRCULATIONAHA.106.637793</pub-id><pub-id pub-id-type="pmid">17190864</pub-id></mixed-citation></ref><ref id="CR34"><label>34.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Durrington</surname><given-names>PN</given-names></name><name><surname>Tuomilehto</surname><given-names>J</given-names></name><name><surname>Hamann</surname><given-names>A</given-names></name><name><surname>Kallend</surname><given-names>D</given-names></name><name><surname>Smith</surname><given-names>K</given-names></name></person-group><article-title>Rosuvastatin and fenofibrate alone and in combination in type 2 diabetes patients with combined hyperlipidaemia</article-title><source>Diabetes Res Clin Pract</source><year>2004</year><volume>64</volume><fpage>137</fpage><lpage>151</lpage><pub-id pub-id-type="doi">10.1016/j.diabres.2003.11.012</pub-id><pub-id pub-id-type="pmid">15063607</pub-id></mixed-citation></ref><ref id="CR35"><label>35.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><collab>The ACCORD Study Group</collab></person-group><article-title>Effects of combination lipid therapy in type 2 diabetes mellitus</article-title><source>N Engl J Med</source><year>2010</year><volume>362</volume><issue>17</issue><fpage>1563</fpage><lpage>1574</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa1001282</pub-id><pub-id pub-id-type="pmid">20228404</pub-id></mixed-citation></ref><ref id="CR36"><label>36.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><collab>The ACCORD Study Group and ACCORD Eye Study Group</collab></person-group><article-title>Effects of medical therapies on retinopathy progression in type 2 diabetes</article-title><source>N Engl J Med</source><year>2010</year><volume>263</volume><fpage>233</fpage><lpage>244</lpage></mixed-citation></ref><ref id="CR37"><label>37.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bays</surname><given-names>HE</given-names></name><name><surname>Jones</surname><given-names>PH</given-names></name><name><surname>Mohiuddin</surname><given-names>SM</given-names></name><name><surname>Kelly</surname><given-names>MT</given-names></name><name><surname>Sun</surname><given-names>H</given-names></name><name><surname>Setze</surname><given-names>CM</given-names></name><etal/></person-group><article-title>Long-term safety and efficacy of fenofibric acid in combination with statin therapy for the treatment of patients with mixed dyslipidemia</article-title><source>J Clin Lipidol</source><year>2008</year><volume>2</volume><fpage>426</fpage><lpage>435</lpage><pub-id pub-id-type="doi">10.1016/j.jacl.2008.10.001</pub-id><pub-id pub-id-type="pmid">21291776</pub-id></mixed-citation></ref></ref-list><fn-group><fn><p>Clinical Trial Registration Number: <ext-link ext-link-type="uri" xlink:href="http://www.clinicaltrials.gov">www.clinicaltrials.gov</ext-link>. NCT00463606, NCT00300482</p></fn></fn-group></back></article>